MS Drug Laquinimod Linked to 8 Non-Fatal Cardiovascular Events
Following findings that eight patients experienced significant, non-life threatening heart incidents, Teva Pharmaceutical Industries Ltd. And Active Biotech AB have ceased phase-2 and phase-3 clinical trial studies of Laquinimod. Laquinimod is used for the treatment of multiple sclerosis and Huntington Disease. The U.S. Food and Drug Administration (FDA) requires phase 3 clinical trial completion before… Continue reading